Ultragenyx Pharmaceutical Inc. (RARE): Price and Financial Metrics

RARE POWR Grades

• RARE scores best on the Value dimension, with a Value rank ahead of 66.27% of US stocks.
• The strongest trend for RARE is in Growth, which has been heading down over the past 52 weeks.
• RARE ranks lowest in Sentiment; there it ranks in the 7th percentile.

RARE Stock Summary

• The ratio of debt to operating expenses for Ultragenyx Pharmaceutical Inc is higher than it is for about merely 10.84% of US stocks.
• RARE's price/sales ratio is 14.8; that's higher than the P/S ratio of 87.46% of US stocks.
• Revenue growth over the past 12 months for Ultragenyx Pharmaceutical Inc comes in at 125.44%, a number that bests 94.55% of the US stocks we're tracking.
• If you're looking for stocks that are quantitatively similar to Ultragenyx Pharmaceutical Inc, a group of peers worth examining would be SLDB, RGNX, EDIT, MTEM, and DRNA.
• RARE's SEC filings can be seen here. And to visit Ultragenyx Pharmaceutical Inc's official web site, go to www.ultragenyx.com.

RARE Valuation Summary

• In comparison to the median Healthcare stock, RARE's EV/EBIT ratio is 161.43% lower, now standing at -18.
• RARE's price/earnings ratio has moved up 5 over the prior 92 months.
• Over the past 92 months, RARE's price/sales ratio has gone NA NA.

Below are key valuation metrics over time for RARE.

RARE Growth Metrics

• Its 3 year price growth rate is now at -1.54%.
• Its year over year net cashflow from operations growth rate is now at 43.03%.
• Its 3 year net income to common stockholders growth rate is now at -83.41%.

Over the past 15 months, RARE's revenue has gone up $237,531,000.

The table below shows RARE's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2021-06-30	359.382	-349.121	-351.425
2021-03-31	334.116	-196.414	-203.682
2020-12-31	271.03	-132.22	-186.566
2020-09-30	215.081	-141.807	-256.36
2020-06-30	159.411	-168.346	-300.509
2020-03-31	121.851	-344.76	-424.996

RARE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• RARE has a Quality Grade of D, ranking ahead of 11.33% of graded US stocks.
• RARE's asset turnover comes in at 0.234 -- ranking 185th of 681 Pharmaceutical Products stocks.
• ADMS, AVDL, and QGEN are the stocks whose asset turnover ratios are most correlated with RARE.

The table below shows RARE's key quality metrics over time.